

## Contents and publications

<b>Chapter 1.</b>	Introduction	11
<b>Chapter 2.</b>	Development of a real-time quantitative assay for detection of Epstein-Barr Virus. (Journal of Clinical Microbiology. 2000;38:712-715)	53
<b>Chapter 3.</b>	Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic hematopoietic stem cell transplantation and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted stem cell transplantation. (Blood. 2001;98:972-978)	67
<b>Chapter 4.</b>	Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. (British Journal of Haematology. 2001;113:814-821)	91
<b>Chapter 5.</b>	Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and pre-emptive rituximab in high-risk patients after allogeneic hematopoietic stem cell transplantation. (Blood. 2002;99:4364-4369)	111
<b>Chapter 6.</b>	Recipients of an allogeneic hematopoietic stem cell graft not recovering Epstein-Barr virus (EBV) specific immunity are at risk to develop high-level EBV load reactivation and EBV-lymphoproliferative disease.	131
<b>Chapter 7.</b>	General discussion	153
<b>Chapter 8.</b>	Summary / Samenvatting	167
	List of publications	174
	Dankwoord	176
	Curriculum vitae	179